LifeScience Biologics
Harbour BioMed Forecasts Record H1 2026 Profit as Strategic Partnerships Drive Growth
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutic...
July 27, 2026 | Company results
ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...
July 27, 2026 | News
Laminar Pharma Completes Pivotal Phase 2b/3 Trial of LAM561 in Newly Diagnosed Glioblastoma
Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, announced that the last patient has c...
July 27, 2026 | News
Nova Biomedical Expands Cell Line Development Portfolio with NanoCellect Technology Acquisition
Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Bio...
July 27, 2026 | News
Tikva Allocell Raises $8M Series A to Advance Off-the-Shelf CAR-T Therapy for Solid Tumours
Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targ...
July 24, 2026 | News
Nona Biosciences Partners with MedUni Vienna to Advance Fully Human Antibody Research
Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice® transgenic mouse technology platform for translational antibody ...
July 24, 2026 | News
Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303
Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...
July 24, 2026 | News
Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs
Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...
July 22, 2026 | News
The Bioreactors Are Ours. The Consumables Are Not.
A new biologics plant is one of the easier things in medicine to photograph. The bioreactors are large and gleaming, the capacity figures are big and round...
July 22, 2026 | Analysis
Generative Bionics Unveils Gene.01 Humanoid Robot Built in Just Six Months
Built in six months, Gene.01 senses touch, proximity, force, and temperature, and it is released with its open-sourced robot model that gives Physical AI d...
July 22, 2026 | News
Rege Nephro Raises $10.6M to Advance iPS Cell-Based Kidney Disease Pipeline
inancing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline Rege Nephro Co., Ltd. ("Rege Nephr...
July 22, 2026 | News
Vector Partners with Caresyntax to Build Real-World Evidence Programme for Opioid-Sparing Surgical Platform
Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative reg...
July 21, 2026 | News
China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer
SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...
July 21, 2026 | News
Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced NSCLC
Akeso, Inc. (9926.HK) (announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2...
July 21, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
